Leading Otolaryngologists Team Up with Frequency Therapeutics in National Clinical Trial
Albany, NY – (June 9th, 2022) The mission at Albany ENT & Allergy Services (AENT), the preeminent private otolaryngology practice in the Capital Region, is to offer superior ear, nose, throat, allergy and sleep care to each one of its Capital Region patients. But AENT’s commitment to its community also includes participation in the development of new treatments and medical advancements in all aspects of Otolaryngology.
Consistent with that, AENT today announced it is participating in a nationwide clinical trial of a novel regenerative medicine candidate that may help restore hearing in patients with sensorineural hearing loss (SNHL). SNHL, which is often caused by exposure to loud sounds, aging, infections, medications that are toxic to the ear or hearing loss that can occur suddenly, is the most common form of hearing loss, affecting more than 41 million Americans.
AENT is currently recruiting adults with noise-induced and sudden SNHL who may qualify for a clinical trial of FX-322, a drug candidate designed to regenerate sensory cells necessary for healthy hearing. Sponsored by Frequency Therapeutics, the study is placebo-controlled and will evaluate outcomes in speech perception, a key measure of hearing function.
“We are delighted to be participating in this potentially game changing research,” stated Dr. Nora Perkins, senior partner at AENT, “We believe this drug candidate has the potential to help thousands upon thousands of our patients.” Added Dr. Gavin Setzen, AENT’s President, “We encourage anyone, even with the slightest symptoms, to get their hearing checked. Untreated hearing loss can, unfortunately, have a huge impact on a person’s health and quality of life.”
To inquire about participating in the FX-322 clinical study, please go to https://www.clarahealth.com/studies/hearing-study
About Albany ENT & Allergy Services
Albany ENT & Allergy Services is a comprehensive practice devoted to the care of adults and children with disorders of the ear, nose, throat, head and neck. It serves the Capital Region from two locations-Albany and Clifton Park-and specializes in allergy diagnosis and immunotherapy as well as sinus, nasal, parathyroid and thyroid surgeries and sleep medicine.
About Frequency Therapeutics
Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore
human function – first in hearing loss and then in multiple sclerosis (MS) – by developing
therapeutics that activate a person’s innate regenerative potential within the body through the
activation of progenitor cells. Frequency’s hearing research focuses on cochlear restoration and
auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first
to show statistically significant and clinically meaningful hearing improvements in clinical trials
for sensorineural hearing loss.
Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, the Scripps Research Institute and Cambridge Enterprises Limited.